Skip to main content
. Author manuscript; available in PMC: 2015 Aug 1.
Published in final edited form as: Cancer Lett. 2014 Apr 24;350(0):25–33. doi: 10.1016/j.canlet.2014.04.016

Fig. 2. Effect of S-NACH, tinzaparin, and gemcitabine on MPanc96 tumor growth in vivo.

Fig. 2

Representative open-cavity bioluminescence images of mice in each group taken at autopsy showing the effect of S-NACH, tinzaparin, and gemcitabine on tumor growth in vivo. Orthotopic pancreatic tumors developed from MPanc96 cells expressing the luciferase gene and were treated with S-NACH (20 mg/kg body weight daily) or tinzaparin (5 mg/kg body weight daily). Gemcitabine (100 mg/kg body weight) was injected intraperitoneally twice a week alone or in combination with either S-NACH or tinzaparin. Bioluminescence images showed reduction in tumor volume in treated groups at the end of the study (4 weeks).